

CMMI Evaluation Digest September 2025

09/26/2025



CMS Innovation Center Evaluation Digest



September 2025

This newsletter highlights recently released Centers for Medicare & Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (Innovation Center) evaluation reports and publications. You can access reports by going to the [evaluations and research reports page](#) of the [Innovation Center website](#).

Reports highlighted in this edition:

- Maternal Opioid Misuse (MOM) Model
- Enhancing Oncology Model (EOM)
- End-Stage Renal Disease Treatment Choices (ETC) Model

Maternal Opioid Misuse (MOM) Model

Evaluation Findings through 2024 - Key Takeaways:

The MOM Model is a patient-centered service delivery model that aims to improve the quality of care for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD) and their infants. The CMS Innovation Center supported

awardees in seven States (Colorado, Indiana, Maine, New Hampshire, Tennessee, Texas, and West Virginia) to implement the MOM Model with care delivery partners through December 2024.

Key Findings in the report include:

Care quality improvements encompass beneficiaries' complex needs. MOM Model beneficiaries faced complex and overlapping health, behavioral and social challenges that demanded flexible, trauma-informed care.

Due to enrollment levels in the model, CMS was unable to perform impact estimates on outcomes of interest. Nonetheless, promising practices have emerged as the MOM Model demonstrates how states can advance integrated care for pregnant and postpartum individuals with opioid use disorder in Medicaid by aligning services with patients' full range of medical, behavioral and social needs.

Sustainability efforts took shape across three reinforcing domains: securing long-term funding, strengthening leadership and institutional support, and extending the model's reach through workforce development and the spread of effective practices.

The Two Page Overview:

- [Findings At-a-Glance \(PDF\)](#)

The Report (includes an Executive Summary):

- [Fourth Annual Evaluation Report \(PDF\)](#)
- [Executive Summary starts on page 8](#)

Additional Supporting Materials:

- Appendix: Methods and Supplemental Analyses starts on page 78
- Model Page: [Maternal Opioid Misuse \(MOM\) Model](#)



Enhancing Oncology Model (EOM)

Evaluation of Performance Period 1 (July–December 2023) - Key Takeaways:

The Enhancing Oncology Model (EOM) is a voluntary model that uses financial and quality incentives to improve care and reduce Medicare spending for patients with seven prevalent cancer types. The goal of the model is to reshape cancer care by encouraging oncology practices to provide high-quality, patient-centered care while reducing Medicare spending. It is an episode-based payment model where participants are financially accountable for the total cost of a 6-month episode of care involving systemic cancer therapies. EOM builds on the Oncology Care Model (OCM) (July 2016–June 2022) by focusing on cancer types that showed savings, focusing financial incentives, requiring practices to collect electronic Patient-Reported Outcomes, and encouraging shared decision-making to empower patients.

The first evaluation report looks at 6-month episodes that started by December 31, 2023. Key findings from the report include:

- Most EOM practices brought prior experience in value-based cancer care from OCM.
- Practices reported a focus on value-based pharmacy interventions, which may have driven reductions in Part B cancer therapy spending in EOM's first 6 months. Their efforts to reduce avoidable acute care, however, did not lead to observable impacts in acute care spending.
- EOM likely led to payment reductions without changing the quality of care in its first 6 months, but after accounting for payments to participants, estimates suggest net losses to Medicare.

The Two Page Overview:

- [Findings At-a-Glance \(PDF\)](#)

The Report (includes an Executive Summary):

- [First Annual Evaluation Report \(PDF\)](#)
- [Executive Summary \(PDF\)](#)

Additional Supporting Materials:

- Appendix: [Data and Methods \(PDF\)](#)
- Model Page: [Enhancing Oncology Model \(EOM\)](#)
- Related Model: [Oncology Care Model \(OCM\)](#)



End-Stage Renal Disease Treatment Choices (ETC) Model

Evaluation Findings through December 2023 - Key Takeaways:

The End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model is intended to encourage greater use of home dialysis and kidney transplantation among ESRD Medicare patients, while reducing Medicare expenditures and preserving or enhancing quality of care. The ETC Model is proposed to end December 31, 2025. Features of the model include:

- During the first three years of the model (2021-2023), CMS applied positive adjustments to Medicare payments to participating ESRD facilities and Managing Clinicians for treating home dialysis patients.
- In July 2022, CMS began adjusting payments to participating ESRD facilities and Managing Clinicians upward or downward based on patient use of home dialysis and transplantation.
- In July 2023, CMS started providing additional support to participating ESRD facilities and Managing Clinicians treating patients who are covered by both Medicare and Medicaid or receive assistance with their prescription drug costs as part of their Part D plan (known as the Low Income Subsidy).

The third annual evaluation report covers the first 3 years of the ETC Model (calendar years 2021-2023). Key findings from the report include:

- There was an increase in the frequency of home dialysis training but no increase in the overall use of home dialysis.
- There was no impact on transplant waitlisting or on living donor transplant rates, which are incentivized by the model.
- There was a net increase in Medicare payments and no decline in quality of care for dialysis patients.

The Two Page Overview:

- [Findings At-a-Glance \(PDF\)](#)

The Report (includes an Executive Summary):

- [Third Annual Report \(PDF\)](#)
- [Executive Summary \(PDF\)](#)

Additional Supporting Materials:

- Appendix: [Data and Methods \(PDF\)](#)
- Model Page: [End-Stage Renal Disease Treatment Choices \(ETC\) Model webpage](#)

